Stem Cell Therapy for LGMD in India

EDITORIAL GOVERNANCE & MEDICAL REVIEW

Clinical E-E-A-T Verified

✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
✓
Clinical Governance Protocol: SOP-LGMD-08 (Investigational Cellular Protocol)

• Last Clinical Review: September 2026 | Next Scheduled Re-Audit: March 2027

View Editorial Standards →

Condition Overview & Research Scope

Clinical Overview & Biological Mechanism

Pathology, cellular action of Mesenchymal Stem Cells (MSCs), and investigational intent

The Pathology:

Limb-Girdle Muscular Dystrophy (LGMD) is a group of rare genetic myopathies characterized by progressive wasting of the proximal shoulder and pelvic girdle musculature.

The Cellular Mechanism:

Umbilical cord-derived or autologous Mesenchymal Stem Cells (MSCs) deliver targeted paracrine signaling. They secrete bio-trophic factors (VEGF, IGF-1, HGF) that:

Downregulate chronic myofiber inflammation and reduce progressive muscle fibrosis.
Stimulate local endogenous muscle precursor cell activity.
Stabilize membrane integrity to slow muscle tissue breakdown.

Investigational Intent:

This is an adjunctive, non-curative cellular intervention intended to preserve residual muscle strength, support functional stability, and enhance overall quality of life alongside standard physical therapy.

Clinical Eligibility & Selection Criteria

Candidate Screening & Safety Triage

Inclusion criteria, absolute safety exclusions, and pre-arrival diagnostic clearance

Eligible Profiles:

Confirmed LGMD diagnosis (via genetic testing panel, muscle biopsy, or elevated serum Creatine Kinase / EMG patterns).
Ambulatory or partially ambulatory individuals with preserved proximal function, or non-ambulatory patients focused on maintaining upper-limb and trunk stability.
Baseline forced vital capacity (FVC) > 60% of predicted value; deemed medically fit for international air travel.

Exclusion Criteria (Non-Candidates):

Severe unmanaged dilated cardiomyopathy or respiratory failure requiring acute mechanical ventilation.
Active systemic infections, active malignancies, or severe unmanaged medical comorbidities.

Pre-Arrival Medical Clearance:

International candidates must submit recent pulmonary function tests (PFTs), cardiac 2D-echocardiograms, genetic reports, and mobility video footage for neurology board clearance prior to travel confirmation.

Targeted Clinical Objectives

Potential Improvements & Realistic Clinical Boundaries

Reported functional goals alongside documented non-responder rates and realistic limits

Biological responses vary widely by genetic subtype and stage of muscle fibrosis. Outcomes cannot be guaranteed, and cellular therapy does not replace conventional rehabilitation or supportive cardiology/pulmonology care.

Pelvic & Trunk Stability: Potential support in proximal hip stability, assisting in sit-to-stand transitions and wheelchair transfers.

Shoulder & Distal Arm Stamina: Better endurance for self-feeding, keyboard use, personal grooming, and overhead reaching.

Fatigue Resistance & Endurance: Measurable reduction in systemic physical exhaustion following light daily tasks.

Respiratory Maintenance: Preservation of diaphragmatic endurance when combined with daily targeted pulmonary physiotherapy.

Documented Clinical Realities:

No Gene Correction: MSCs do not replace or repair defective genetic sequences.

Non-Responder Rate: Approximately 20–30% of patients experience minimal functional response, and progressive natural disease decline may continue.

Delayed Onset: Clinical effects typically require 8 to 12 weeks to manifest; immediate restoration should not be expected.

Safety Profile & Governance

Clinical Safety Profile & Anticipated Adverse Reactions

Anticipated transient reactions, procedural safeguards, and long-term surveillance

While clinical-grade, unmanipulated MSCs exhibit a well-documented safety profile, patients must be informed of known potential adverse events:

Common & Transient (Day 1–3):

Low-grade post-infusion fever (< 38°C / 100.4°F), temporary muscle aches, fatigue, or mild local tenderness at intramuscular delivery sites.

Rare Risks:

Allergic hypersensitivity reactions or localized hematoma (managed under continuous bedside telemetry and vital sign monitoring).

Patient Safety Measures: Continuous pulse oximetry, blood pressure tracking, and immediate access to full tertiary-care resuscitation facilities during every session.

Treatment Schedule & Roadmap

Step-by-Step Treatment Schedule & In-Hospital Workflow

Structured clinical itinerary during your stay in India (5 to 7 Days)

Total Program Length: 4 to 6 days on an outpatient hospital daycare and monitored recovery basis.

Day 1 (Comprehensive Hospital Workup):

In-person neurological consultation, baseline Manual Muscle Testing (MMT), and Vignos/Brooke functional scoring.

Confirmatory lab checks: Complete Blood Count, Liver & Renal function, Cardiac Biomarkers, and baseline spirometry.

None:

Days 2–3 (Cell Delivery & Supervised Rehabilitation):

Certified, cryopreserved, or formulated MSCs administered via monitored intravenous infusion and/or targeted local intramuscular protocols.
Individualized neuromuscular physiotherapy, gentle passive stretching, and diaphragmatic breathing coaching.

Days 4–5 (Post-Infusion Assessment & Rest):

Clinical review of vital stability, discharge documentation, and individualized home-physiotherapy plan issuance.

Day 6 (Discharge & Return Flight Clearance):

Final review and fit-to-fly clinical sign-off.

Longitudinal Remote Follow-Up:

Scheduled telemedicine evaluations at Months 1, 3, 6, and 12, coordinated directly with the patient's home neurologist.

Strategic Hospital Advantages

Why Receive Care at Our Specialized Center in India?

Super-specialist clinical oversight, cGMP cleanroom facilities, and high cell viability

Senior Specialist Oversight: Protocols led by board-certified neurologists holding post-doctoral DM/DNB credentials and experienced cellular biologists.

Cell Quality & Traceability: Clinical-grade MSCs processed in ISO Class 5/7 cleanrooms; batch-tested for high viability (>85%), sterility, negative mycoplasma, endotoxin clearance, and surface marker characterization (CD73+, CD90+, CD105+ / CD34-, CD45-).

Transparent Pricing:

Comprehensive all-inclusive medical packages range between $5,000 and $7,800 USD (covering clinical biologicals, hospital daycare fees, physician consultations, and baseline routine labs). Detailed written cost estimates are provided before booking.

Estimated Costs & Package Inclusions

Treatment Costs & Comparative Package Inclusions

Transparent international pricing with comprehensive hospital, cellular, and logistical inclusions

Package Range Transparent Pricing

$5,200 – $7,800 USD

(Comprehensive package covering targeted UC-MSCs, procedural suites, specialist fees, and 12-month monitoring).

Clinical Objective Investigational Care

Limb-Girdle Muscular Dystrophy (LGMD) Care

(Administered under strict ISO Class 5 cleanroom standards and institutional ethics oversight).

Country / Region	Typical Package Range	Waiting Period	Clinical Accreditation
India (Our Specialized Centers)	$5,200 – $7,800 USD	1 – 2 Weeks	NABH / JCI Accredited
United States	$35,000 – $65,000 USD	3 – 6 Months	Clinical Trial Gated
Germany & Switzerland	$28,000 – $55,000 USD	2 – 4 Months	Private Specialty Only
Panama / Mexico	$18,000 – $32,000 USD	2 – 4 Weeks	Variable Regional

Package Inclusions:

Pre-procedure specialty diagnostics, baseline scans, and multidisciplinary doctor evaluations.

cGMP cleanroom certified cellular harvesting, flow-cytometry viability testing (>85%), and procedural suite fees.

Government Medical Visa (MED Visa) invitation assistance and complimentary chauffeured airport transfers.

Dedicated bilingual case coordinator and 12 months of structured remote post-procedure monitoring.

International Patient Services

Dedicated Support for International Patients & Families

Full medical concierge care, government visa assistance, and airport transit

Medical Visa (MED) Assistance:

Official hospital visa invitation letters issued within 24–48 hours for patient and accompanying caregivers (with FRRO guidance).

Dedicated Case Coordinator:

Single bilingual contact managing hospital appointments, documentation, and logistical support.

Airport & Ground Transit:

Complimentary private airport pick-up/drop-off with dedicated wheelchair-accessible transit.

Language & Dietary Care:

Multi-language translators (Arabic, Russian, French) and custom international meal arrangements (Halal, Vegetarian, Continental).

Travel & Logistics

Logistics & Accessible Accommodation

Daycare outpatient protocol, nearby wheelchair-accessible partner lodging, and daily transfers

Daycare Convenience: Treatment and rehabilitation are completed in morning sessions; patients rest in private accommodation each afternoon.

Barrier-Free Lodging: Partnerships with 4-star hotels and serviced apartments located within 10–15 minutes of the hospital, featuring step-free access, elevators, roll-in showers, and kitchenettes.

Daily Commutes: Coordinated daily transfers between local lodging and the medical center to prevent physical fatigue.

Regulatory & Ethics

Regulatory Disclosures & Ethical Declarations

Statutory compliance under ICMR-DBT National Guidelines and vital medication advisories

Investigational Therapy Notice:

Cell-based therapy for Limb-Girdle Muscular Dystrophy is categorized as an investigational cellular intervention under the National Guidelines for Stem Cell Research by the Indian Council of Medical Research (ICMR) and the Central Drugs Standard Control Organisation (CDSCO). It is not an approved routine standard of care or a definitive cure.

No Genetic Alteration: MSC therapy does not alter defective genetic codes or restore absent structural proteins directly; it acts as an adjunctive supportive biological treatment.

Medication Continuity: Patients must never discontinue or alter existing medical treatments, cardioprotective prescriptions, or physical therapy regimens without direct authorization from their primary treating neurologist.

Scientific Citations

Peer-Reviewed Clinical Literature & Scientific Context

Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms

Scientific Clarification on Cell Types: Studies 1 and 3 evaluate autologous bone marrow mononuclear/stem cells (BMMNCs), which are harvested directly from the patient’s bone marrow. Studies 2 and 4 evaluate culture-expanded Mesenchymal Stem Cells (MSCs), including umbilical cord-derived allogeneic cells. These references are provided to support informed discussions between patients and their domestic physicians.

Clinical Context:

 Rajput et al. (Frontiers in Neurology, 2015)

PubMed: 26082747 ↗

Rajput SJ, et al. Safety and efficacy of autologous bone marrow-derived mononuclear/stem cells in patients with muscular dystrophy, including limb-girdle muscular dystrophy. Front Neurol. 2015;6:114. PubMed ID: PMID: 26082747

Clinical Context: Open-label clinical assessment of autologous bone marrow mononuclear/stem cells in progressive muscular dystrophies, demonstrating acceptable safety and functional stability in treated LGMD cohorts.

 Klimczak et al. (Stem Cells International, 2018)

PubMed: 29854005 ↗ PMC5962058 ↗

Klimczak Z, et al. Mesenchymal Stem/Stromal Cells for Skeletal Muscle Regeneration in Neuromuscular Disorders: Clinical Applications and Mechanism of Action. Stem Cells Int. 2018;2018:4093407. PubMed ID: PMID: 29854005 | PMCID: PMC5962058

Clinical Context: Comprehensive review of MSC clinical trials highlighting mechanisms of action, including down-regulation of muscle inflammation and the reduction of progressive muscle fibrosis.

 Sharma et al. (Case Reports in Neurological Medicine, 2014)

PubMed: 25165576 ↗ PMC4142750 ↗

Sharma A, et al. Autologous Bone Marrow Mononuclear/Mesenchymal Cell Transplantation in a Case of Limb-Girdle Muscular Dystrophy. Case Rep Neurol Med. 2014;2014:672049. PubMed ID: PMID: 25165576 | PMCID: PMC4142750

Clinical Context: Case report detailing autologous cell transplantation paired with neuro-rehabilitation in LGMD, tracking functional independence and manual muscle testing changes over 12 months.

 Lv et al. (Cell Transplantation / Stem Cells Transl Med, 2014)

PubMed: 24442609 ↗

Lv FJ, et al. Concise Review: The Surface Markers and Identity of Human Mesenchymal Stem Cells in Muscle Repair and Skeletal Disease. Stem Cells Transl Med. 2014;3(3):328–337. PubMed ID: PMID: 24442609

Clinical Context: Review of human MSC surface characterization and the trophic mechanisms (IGF-1, HGF secretion) that support muscle fiber stabilization.

Frequently Asked Questions

Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Limb-Girdle Muscular Dystrophy (LGMD)

No, stem cell therapy is not recognized as a definitive or permanent cure. Under Indian Council of Medical Research (ICMR) and CDSCO clinical guidelines, cellular therapy for Limb-Girdle Muscular Dystrophy (LGMD) is an investigational and supportive treatment. Its objective is to modulate pathogenic immune activity, release neurotrophic and cytoprotective paracrine factors, and slow down progression to improve quality of life under strict institutional ethics oversight.

Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act primarily through paracrine immunomodulation and secretome release. They downregulate pro-inflammatory cytokines, modulate hyperactive cytotoxic T-cells, inhibit excessive fibrotic scarring, and secrete restorative growth factors (such as HGF, VEGF, BDNF, and IL-10) that support microvascular circulation and cellular tissue survival.

The comprehensive outpatient daycare protocol requires approximately 5 to 7 Days in India. Day 1 involves baseline diagnostic blood panels, imaging, and specialty evaluation by a Neuromuscular Medicine & Rehabilitation board. Days 2 and 3 include monitored cellular infusion (Targeted Systemic IV & Focal Muscle Infiltration) under vital telemetry, followed by post-procedure observation, mobility guidance, and fit-to-fly clearance on Day 7.

Certified cGMP-processed allogeneic UC-MSCs possess an established safety profile with zero risk of donor graft-versus-host disease (GvHD). Common transient reactions include self-limiting low-grade fever (< 38°C / 100.4°F), temporary fatigue, or mild injection-site soreness resolving within 24–48 hours. Patients undergo pre-infusion safety checks and continuous bedside monitoring.

Comprehensive international treatment packages range from $5,200 – $7,800 USD. This transparent pricing includes clinical-grade certified UC-MSC biologicals (flow-cytometry verified >85% viability), specialized hospital procedural suites, doctor consultations, routine baseline safety labs, medical visa (MED) invitation support, and 12 months of structured remote follow-up.

Before confirming medical travel, international patients must submit recent clinical diagnostic reports (specialty scans, blood chemistry, disease-specific antibody panels, or biopsy records) for preliminary evaluation by our medical board. Our clinical team reviews the records within 24 to 48 hours to confirm candidacy before issuing official visa invitation letters.

✓
Accreditations: NABH-Accredited Inpatient Tertiary Hospital | ISO Class 5 Cleanroom Processing
✓
Statutory Oversight: Institutional Committee for Stem Cell Research (IC-SCR) & Registered Institutional Ethics Committee (IEC)
✓
Regulatory Alignment: Conducted under the ICMR-DBT National Guidelines for Stem Cell Research (India)
✓
Direct International Triage:
WhatsApp / Phone: +91-7744005984

Email: contact@stemcelltherapyinindia.com

PARTNER HOSPITALS TREATING LIMB-GIRDLE MUSCULAR DYSTROPHY (LGMD):

RELATED PROTOCOLS:

Category	Details	Cost
🏥 Medical Procedure Cellular processing & specialist fees	Standard Protocol	$4,200
🏨 Accommodation Private room near hospital	7 nights @ $35/night	$245
🍽 Meals & Nutrition Dietary plan for patient & companions	7 days × 2 person(s) @ $25/day	$350
🚗 Local Transfers & Visa	Ground handling & priority transit	$200
💎 Total Estimated Budget All-inclusive medical + logistics	Combined estimate for 7 days (2 travelers)	$4,995